Scientists Are Attempting to Reprogram Old Human Cells to Be Young Again

Key Points:

• Life Biosciences has initiated the world's first gene therapy clinical trial targeting optic neuropathies, specifically open-angle glaucoma, using a drug called ER-100 that aims to regenerate the optic nerve by reprogramming aging cells.
• The therapy targets three genes (OCT4, SOX2, and KLF4) to revert cells to a more youthful, stem-like state, potentially restoring vision, but carries risks including the proliferation of cancerous cells.
• Previous animal studies showed partial success in reversing cellular aging but also revealed dangers such as tumor development, prompting refinements to improve safety before human trials.
• This Phase 1 trial represents a pioneering effort to test whether restoring epigenetic information can reverse age-related damage in humans, with the eye chosen as a trial site due to its importance and relative safety for experimental treatments.
• Current glaucoma treatments only preserve existing vision without restoration, making this gene therapy a potentially groundbreaking advancement for millions affected by the disease.